"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below ...

Teva’s first pair of true winter boots deliver on their promises. They’re not meant for arctic adventures but are great at ...

Israeli generics giant Teva Pharmaceutical Industries today reported results for the year and the quarter ended December 31, ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

Reports Q4 revenue $4.2B, consensus $4.12B. Richard Francis, Teva‘s (TEVA) President and CEO, said: “2024 marked a transformative year for ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Wealth host Brad Smith analyzes the latest earnings reports from Wall Street. VF Corp's (VFC) stock climbed following ...